Pricing & Access· August 8, 2026 · 14 min read
Novo Nordisk portfolio dossier (Q2 2026): Wegovy, CagriSema & obesity pipeline
By Ran Chen#Novo Nordisk#Semaglutide#Wegovy
Topic
CagriSema
CagriSema (cagrilintide/semaglutide) fixed-dose combination clinical trial readouts, REDEFINE and REIMAGINE data, and head-to-head positioning against tirzepatide.